Journal Article

DZNE-2025-00286

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment.

Bolsewig, K. ; Willemse, E. A. J. ; Sánchez-Juan, P. ; Rábano, A. ; Martínez, M. ; Doecke, J. D. ; Bellomo, G. ; Vermunt, L. ; Alcolea, D. ; Halbgebauer, S.DZNE* ; In 't Veld, S. ; Mattsson-Carlgren, N. ; Veverova, K. ; Fowler, C. J. ; Boonkamp, L. ; Koel-Simmelink, M. ; Hussainali, Z. ; Ruiters, D. N. ; Gaetani, L. ; Toja, A. ; Fortea, J. ; Pijnenburg, Y. ; Lemstra, A. W. ; van der Flier, W. M. ; Hort, J. ; Otto, M. ; Hansson, O. ; Parnetti, L. ; Masters, C. L. ; Lleó, A. ; Teunissen, C. E. ; Del Campo Milán, M.

2025
Springer Nature [London]

This record in other databases:    

Please use a persistent id in citations: doi:10.1038/s41467-025-56293-z

Abstract: DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we evaluate plasma DDC, measured by proximity extension assay, and the effect of dopaminergic treatment in three independent LBD (with a focus on dementia with Lewy bodies (DLB) and Parkinson's disease (PD)) cohorts: an autopsy-confirmed cohort (n = 71), a large multicenter, cross-dementia cohort (n = 1498) and a longitudinal cohort with detailed treatment information (n = 66, median follow-up time[IQR] = 4[4, 4] years). Plasma DDC was not altered between different LBDs and other disease groups or controls in absence of treatment. DDC levels increased over time in PD, being significantly associated to higher dosages of dopaminergic treatment. This emphasizes the need to consider treatment effect when analyzing plasma DDC, and suggests that plasma DDC, in contrast to CSF DDC, is of limited use as a diagnostic biomarker for LBD, but could be valuable for treatment monitoring.

Keyword(s): Humans (MeSH) ; Lewy Body Disease: drug therapy (MeSH) ; Lewy Body Disease: blood (MeSH) ; Lewy Body Disease: cerebrospinal fluid (MeSH) ; Dopa Decarboxylase: metabolism (MeSH) ; Male (MeSH) ; Female (MeSH) ; Aged (MeSH) ; Parkinson Disease: drug therapy (MeSH) ; Parkinson Disease: blood (MeSH) ; Parkinson Disease: cerebrospinal fluid (MeSH) ; Biomarkers: blood (MeSH) ; Biomarkers: cerebrospinal fluid (MeSH) ; Aged, 80 and over (MeSH) ; Middle Aged (MeSH) ; Dopamine Agents: therapeutic use (MeSH) ; Cohort Studies (MeSH) ; Longitudinal Studies (MeSH) ; Dopa Decarboxylase ; Biomarkers ; Dopamine Agents

---

Contributing Institute(s):

1. Clinical Study Center (Ulm) (Clinical Study Center (Ulm))

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2025

---

Database coverage:
; ; ; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Agriculture, Biology and Environmental Sciences ; Current Contents - Life Sciences ; Current Contents - Physical, Chemical and Earth Sciences ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF >= 15 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection ; Zoological Record

---